Shows
Viremic – Cases in HIVCase 16. Mpox After the OutbreakA 33-year-old man with HIV presents with a flu-like syndrome and a disseminated vesicular rash after sexual contact with a new partner. Differential diagnosis includes mpox, syphilis, other STIs, HSV and disseminated VZV. Listen as Eileen and her guest, Dr. Shauna Gunaratne work through the mpox diagnosis, and discuss the 2022 mpox outbreak, along with evidence-based recommendations for testing, treatment, and prevention.References Cited:Akter F, Hasan TB, Alam F, et al. Effect of prior immunisation with smallpox vaccine for protection against human Mpox: A systematic review. Rev Med Virol. 2023 Jul;33(4):e2444. Epub 2023 Mar 30. PMID: 36999223.CDC. Monkeypox...
2026-02-1731 minViremic – Cases in HIVHoliday GreetingsHello Viremic listeners. We are taking a break this week and encourage you to take a look back at our past episodes and catch up on any cases you may have missed. We'll be back on January 6, 2026 with a new case to discuss! From all of us at Viremic we hope you have a peaceful, healthy and joyous holiday season!
2025-12-2300 minViremic – Cases in HIVCase 7. Newer Kids on the Block: Novel ARVs for Multidrug ResistanceHow to formulate an effective ART regimen acceptable to 56-year-old man, with unsuppressed HIV, 20+ yr. ART history, extensive drug resistance, and adherence challenges? Listen as Eileen and Chris interpret resistance testing results, discuss barriers to treatment and adherence for this patient, and evaluate the possibility of using one of the novel agents—fostemsavir, ibalizumab, and lenacapavir. What would you do?References and Resources Cited:Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379(7):645-654. PMID: 3010589Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in Adults wi...
2025-09-3031 minViremic – Cases in HIVCase 6. Is More Really More? Optimizing Options for a Healthy PatientHealthy 48-year-old man with HIV for 15 years, stable viral suppression, looking to optimize health—diet, exercise, immune-boosting supplements, safest HIV and HTN meds. Listen as Chris and Eileen discuss their approach to giving patients the good news about their health, health maintenance, supplement use, and whether to stay the course or switch ART regimens in patients who are doing well.Resources:NIH Office of Dietary Supplements: Dietary Supplement Fact Sheets FDA: Information for Consumers on Using Dietary SupplementsRelated NYSDOH AIDS Institute Clinical Guidelines: Primary Care for Adults with HIVSecond-Line ART After Treatment Failure or f...
2025-09-1634 minViremic – Cases in HIVCase 1. Returning to Care – Is Biktarvy Always the Answer?48-yr-old man with HIV for 12 years presented 1 year after his last visit with a history of methamphetamine use, inconsistent engagement in care, and a new diabetes diagnosis. He reported no recent ART and no meth use for about 8 months. On returning to care, his viral load was 250,000 copies/mL, the CD4 count was 230 cells/mm3, creatinine levels were elevated, and genotype testing found a K103N mutation. He was motivated to resume ART. Drs. Scully and Hoffmann evaluate the patient’s new ART options in light of his clinical viremia and comorbidities. References CitedAndreatta K, D’A...
2025-07-0837 min